Adoptive immunotherapy for stage IV renal cell carcinoma: a novel protocol utilizing periodate and interleukin-2-activated autologous leukocytes and continuous infusions of low-dose interleukin-2

No abstract is available for this paper.

• Publication year

  1987

• Venue

  The American Journal of Medicine

• Publication date

  1987-12-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/0002-9343(87)90936-3
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone.

  1987influential reference
• Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer.

  1987cited by this paper
• Anti-tumor properties of lymphocytes activated by the oxidizing mitogens.

  1986cited by this paper
• Interleukin-2 or autologous lymphokine-activated killer cell treatment of malignant glioma: phase I trial.

  1986cited by this paper
• Extravasation of intravascular fluid mediated by the systemic administration of recombinant interleukin 2.

  1986cited by this paper
• Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer.

  1985cited by this paper
• Successful immunotherapy of natural killer-resistant established pulmonary melanoma metastases by the intravenous adoptive transfer of syngeneic lymphocytes activated in vitro by interleukin 2

  1984cited by this paper
• Adoptive immunotherapy of established pulmonary metastases with LAK cells and recombinant interleukin-2.

  1984cited by this paper
• Induction of cytolytic activity by anti-T3 monoclonal antibody. Activation of alloimmune memory cells and natural killer cells from normal and immunodeficient individuals.

  1984cited by this paper
• Site-specific mutagenesis of the human interleukin-2 gene: structure-function analysis of the cysteine residues.

  1984cited by this paper
• Immunologic monitoring of the renal transplant recipient.

  1983cited by this paper
• Lymphokine-activated killer cell phenomenon. Lysis of natural killer- resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes

  1982cited by this paper
• Stimulation of human peripheral blood lymphocytes by periodate, galactose oxidase, soybean agglutinin, and peanut agglutinin: differential effects of adherent cells.

  1977cited by this paper
• Membrane site modified on induction of the transformation of lymphocytes by periodate.

  1972cited by this paper

• Immunotherapy as a potential treatment approach for currently incurable bone metastasis

  2023cites this paper
• Understanding the Hsp90 N-Terminal Dynamics: Structural and Molecular Insights into the Therapeutic Activities of Anticancer Inhibitors Radicicol (RD) and Radicicol Derivative (NVP-YUA922)

  2020cites this paper
• Possible role for cytotoxic lymphocytes in the pathogenesis of acute interstitial nephritis after recombinant interleukin-2 treatment for renal cell cancer

  2005cites this paper
• Correlation of eosinophilia with clinical response in patients with advanced carcinoma treated with low-dose recombinant interleukin-2 and mitomycin C

  2005cites this paper
• Inhaled interleukin-2 in combination with low-dose systemic interleukin-2 and interferon α in patients with pulmonary metastatic renal-cell carcinoma: effectiveness and toxicity of mainly local treatment

  2005cites this paper
• Adoptive immunotherapy of a mouse colon carcinoma with recombinant interleukin-2 alone or combined with lymphokine-activated killer cells or tumor-immune lymphocytes

  2005cites this paper
• Rationale for immunotherapy of renal cell carcinoma

  2004cites this paper
• Time course of the cytotoxicity of blood mononuclears in patients with bladder cancer during endolymphatic immunotherapy with lymphokine-activated killers and recombinant interleukin-2

  1996cites this paper
• Inhalational Interleukin-2 in the Treatment of Pulmonary Metastases in Patients with Renal Cell Carcinoma

  1995cites this paper
• Combination of lymphokine-activated killer cells and interleukin-2 in treating metastatic renal cell carcinoma.

  1994cites this paper
• Synergistic Antimetastatic Effects of Lentinan and Interleukin 2 with Pre‐ and Post‐operative Treatments

  1994cites this paper
• Laboratory correlates of chemoimmunotherapy with low-dose recombinant interleukin-2 and mitomycin C in patients with advanced carcinoma.

  1994cites this paper
• Cytoreductive surgery before high dose interleukin-2 based therapy in patients with metastatic renal cell carcinoma.

  1993cites this paper
• [Study of adoptive immunotherapy with lymphokine-activated killer (LAK) cells and interleukin-2 for metastatic renal cell carcinoma. I. Generation of LAK cells by incubation in serum-free medium].

  1993cites this paper
• Prolonged interleukin-2 (IL-2) treatment can augment immune activation without enhancing antitumor activity in renal cell carcinoma.

  1991cites this paper
• Comparison of suppressor and cytotoxic activity of blood mononuclears during adaptive immunotherapy of cancer patients with lymphokine-activated killer cells with a low dose of recombinant interleukin-2

  1991cites this paper
• Cytokines in anticancer therapy.

  1991cites this paper
• [Usefulness and limitation of immunotherapy of metastatic renal cell carcinoma with autologous lymphokine-activated killer cells and interleukin 2].

  1991cites this paper
• Lymphokines and cytokines as cancer treatment.Immunotherapy realized

  1990cites this paper
• Adoptive Immunotherapy for Renal Adenocarcinoma: Use of Oxidizing Mitogen-Treated Mononuclear Leukocytes and Continuous Infusion of Interleukin-2

  1990cites this paper
• Interleukin 2: Clinical Aspects

  1990cites this paper
• Interleukin 2 and lymphokine-activated killer cell therapy: analysis of a bolus interleukin 2 and a continuous infusion interleukin 2 regimen.

  1990cites this paper
• Repetitive weekly cycles of interleukin 2: effect of outpatient treatment with a lower dose of interleukin 2 on non-major histocompatibility complex-restricted killer activity.

  1989cites this paper
• Antitumor properties of mononuclear cells activated by combined treatment with oxidizing mitogens and interleukin-2: basic and clinical studies.

  1989cites this paper
• A phase II clinical trial of adoptive immunotherapy for advanced renal cell carcinoma using mitogen-activated autologous leukocytes and continuous infusion interleukin-2.

  1989cites this paper
• Adoptive immunotherapy of urologic tumors.

  1989cites this paper
• In vivo biology of recombinant interleukin-2 infusion in sheep: Cardiopulmonary manifestations of an intravascular immune-inflammatory response

  1989cites this paper
• Continuous infusion of recombinant interleukin-2 and lymphokine-activated killer cells in refractory malignancies.

  1989cites this paper
• Therapeutic uses of interleukin-2 and lymphokine-activated killer (LAK) cells.

  1989cites this paper
• Inotropicand VasoactiveDrugTreatmentof Interleukin2 InducedHypotension in Sheep

  1989cites this paper
• Lymphokine activated killer cells

  1989cites this paper
• The cellular immunotherapy of cancer: current and potential uses of interleukin-2.

  1989cites this paper
• Review: Cardiopulmonary Toxicity of Adoptive Immunotherapy

  1988cites this paper